Skip to main content

Loading market data...

ARWR

Arrowhead Pharmaceuticals, Inc.

NASDAQ • United states

$59.22

+$1.99

(+3.48%)

Source: Yahoo Finance · Quote time Oct 20, 2026 14:48 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Arrowhead Pharmaceuticals, Inc. (ARWR)

Unavailable

Quotes may be delayed

$8.37B

Market Cap

355,179

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

Arrowhead Pharmaceuticals, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 177 E COLORADO BLVD, PASADENA, CA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

14 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Arrowhead Pharmaceuticals, Inc..

4 Aug 2026

Arrowhead Pharmaceuticals, Inc. reported Operating or financial results

Arrowhead Pharmaceuticals, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

4 Aug 2026

Arrowhead Pharmaceuticals, Inc. filed Form 10-Q

Arrowhead Pharmaceuticals, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

31 Jul 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Arrowhead Pharmaceuticals, Inc..

27 Jul 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Arrowhead Pharmaceuticals, Inc..

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$69.40M

Total assets (USD)$2.11B

Shareholders' equity (USD)$465.53M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$75.25M	−$170.09M	−$194.28M	−$1.36	10-Q · 4 Aug 2026
Q1 2026	$73.74M	−$141.26M	−$132.73M	−$0.93	10-Q · 7 May 2026
Q4 2025	$264.03M	$40.81M	$30.81M	$0.22	10-Q · 5 Feb 2026
Q2 2025	$27.77M	−$165.55M	−$175.24M	−$1.26	10-Q · 7 Aug 2025
Q1 2025	$542.71M	$381.20M	$370.45M	$2.75	10-Q · 12 May 2025
Q4 2024	$2.50M	−$161.41M	−$173.09M	−$1.39	10-Q · 10 Feb 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $109.00

84.1% upside potential

📈

Strong Buy

Unavailable

👍

Buy

12

⏸️

Hold

1

📉

Sell

0

13 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 14:48 UTC Targets range 74.00–126.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

18

Aug 2026

OLUKOTUN ADEOYE Y

Director

Open-market sale

$86.96 per share

2,000 shares

18

Aug 2026

PERRY MICHAEL S

Director

Open-market sale

$87.30 per share

11,600 shares

15

Jun 2026

Cohen Matthew Gregory

Director

Grant or award

Unavailable per share

11,882 shares

12

May 2026

Lu Hongbo

Director

Open-market sale

$76.88 per share

2,970 shares

23

Apr 2026

Hamilton James C

Chief Medical Officer

Open-market sale

$75.00 per share

10,000 shares

22

Apr 2026

Apel Daniel Joseph

Chief Financial Officer

Open-market sale

$71.35 per share

13,095 shares

5

Mar 2026

Hamilton James C

Chief Medical Officer

Open-market sale

$64.19 per share

10,000 shares

6

Jan 2026

Hamilton James C

Chief Medical Officer

Grant or award

Unavailable per share

75,000 shares

Top Shareholders

Vanguard Group Inc

15,293,121 shares

-4.632% change

12/31/2025

Blackrock, Inc.

14,830,553 shares

-18.341% change

6/30/2026

Avoro Capital Advisors Llc

11,355,555 shares

6.127% change

6/30/2026

Fmr Llc

8,039,804 shares

10.64% change

6/30/2026

Vanguard Portfolio Management Llc

6,351,355 shares

-11.122% change

6/30/2026

Vanguard Capital Management Llc

6,110,953 shares

1.302% change

6/30/2026

State Street Corp

5,694,640 shares

-12.338% change

6/30/2026

Norges Bank

3,896,536 shares

128.608% change

6/30/2026

Invesco Ltd.

3,883,976 shares

18.391% change

6/30/2026

Geode Capital Management, Llc

3,530,612 shares

-17.486% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 14:48 UTC· 1 day ago

Research coverage and investment tools

Arrowhead Pharmaceuticals, Inc. (ARWR) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$59.22 on 20 Oct 2026. That is 38% of the way from its 52-week low of US$36.73 to its 52-week high of US$95.49. Its market capitalisation was US$8.37 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$75.25M	−$170.09M	−$194.28M	−$1.36	—	-226.0%	—	10-Q · 4 Aug 2026 (opens in a new tab)
Q1 2026	$73.74M	−$141.26M	−$132.73M	−$0.93	—	-191.6%	—	10-Q · 7 May 2026 (opens in a new tab)
Q4 2025	$264.03M	$40.81M	$30.81M	$0.22	—	15.5%	$11.33M	10-Q · 5 Feb 2026 (opens in a new tab)
Q2 2025	$27.77M	−$165.55M	−$175.24M	−$1.26	—	-596.2%	—	10-Q · 7 Aug 2025 (opens in a new tab)
Q1 2025	$542.71M	$381.20M	$370.45M	$2.75	—	70.2%	—	10-Q · 12 May 2025 (opens in a new tab)
Q4 2024	$2.50M	−$161.41M	−$173.09M	−$1.39	—	-6,456.5%	−$153.79M	10-Q · 10 Feb 2025 (opens in a new tab)

Cash and equivalents: $69.40M
Total assets: $2.11B
Shareholders' equity: $465.53M

SCHEDULE 13G/A · 14 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Arrowhead Pharmaceuticals, Inc..
8-K · 4 Aug 2026

Arrowhead Pharmaceuticals, Inc. reported Operating or financial results (opens in a new tab)

Arrowhead Pharmaceuticals, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
10-Q · 4 Aug 2026

Arrowhead Pharmaceuticals, Inc. filed Form 10-Q (opens in a new tab)

Arrowhead Pharmaceuticals, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
SCHEDULE 13G/A · 31 Jul 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Arrowhead Pharmaceuticals, Inc..
SCHEDULE 13G/A · 27 Jul 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Arrowhead Pharmaceuticals, Inc..

Insider	Date	Transaction	Shares	Average price	Filing
OLUKOTUN ADEOYE Y Director	18 Aug 2026	Open-market sale (S)	−2,000	$86.96	Form 4 (opens in a new tab)
PERRY MICHAEL S Director	18 Aug 2026	Open-market sale (S)	−11,600	$87.30	Form 4 (opens in a new tab)
Cohen Matthew Gregory Director	15 Jun 2026	Grant or award (A)	+11,882	—	Form 4 (opens in a new tab)
Lu Hongbo Director	12 May 2026	Open-market sale (S)	−2,970	$76.88	Form 4 (opens in a new tab)
Hamilton James C Chief Medical Officer	23 Apr 2026	Open-market sale (S)	−10,000	$75.00	Form 4 (opens in a new tab)
Apel Daniel Joseph Chief Financial Officer	22 Apr 2026	Open-market sale (S)	−13,095	$71.35	Form 4 (opens in a new tab)
Hamilton James C Chief Medical Officer	5 Mar 2026	Open-market sale (S)	−10,000	$64.19	Form 4 (opens in a new tab)
Hamilton James C Chief Medical Officer	6 Jan 2026	Grant or award (A)	+75,000	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Vanguard Group Inc	12/31/2025	15,293,121	-4.632%
Blackrock, Inc.	6/30/2026	14,830,553	-18.341%
Avoro Capital Advisors Llc	6/30/2026	11,355,555	6.127%
Fmr Llc	6/30/2026	8,039,804	10.64%
Vanguard Portfolio Management Llc	6/30/2026	6,351,355	-11.122%
Vanguard Capital Management Llc	6/30/2026	6,110,953	1.302%
State Street Corp	6/30/2026	5,694,640	-12.338%
Norges Bank	6/30/2026	3,896,536	128.608%
Invesco Ltd.	6/30/2026	3,883,976	18.391%
Geode Capital Management, Llc	6/30/2026	3,530,612	-17.486%

Previous close: 57.23 USD
Day range: 56.92 – 59.57 USD
52-week range: 36.73 – 95.49 USD
Volume: 355,179
Market cap: $8.37B
Average volume: 1,814,661
EPS (FY 2025, diluted): −0.01 USD
Shares outstanding: 141.25M
Beta (5Y monthly): 1.36

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 14:48 UTC· 1 day ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:17 UTC· 1 hour ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for ARWR yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.